Tao Jianxin, Nie Yunjuan, Wu Hui, Cheng Liang, Qiu Yuanwang, Fu Juanjuan, Jiang Xiufeng
Wuxi Clinical College, Nanjing Medical University, Wuxi, Jiangsu, China.
Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
J Infect Dev Ctries. 2020 Oct 31;14(10):1138-1145. doi: 10.3855/jidc.13081.
The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly. Critically ill cases of COVID-19 can rapidly progress to acute respiratory distress syndrome and multiple organ failures. However, no effective drugs have been available till now, leading to more than 300,000 deaths up to 29 April 2020. Here, we present a critically ill case utilizing umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs).
A 72-year-old man was admitted, with the diagnosis of COVID-19, ARDS, type-2 diabetes, diabetic nephropathy, renal insufficiency, and hypertension. His clinical condition continually developed to be life-threatening even receiving various treatment options including antiviral therapy and extracorporeal membrane oxygenation. Between 28 February and 8 March 2020, the patient was given 5-time intravenous infusions of UCB-MSCs. His hematological and biochemical indexes, including lymphocytes and renal function improved. Pulmonary static compliance increased significantly and PaO2/FiO2 ratio maintained stable. On March 10, he received lung transplantation.
Our current findings suggested that UCB-MSCs therapy may show some positive effect in treating critical COVID-19 to some extent, for its delaying deterioration of the disease and efficacy in respiratory and renal function, though limited.
2019年冠状病毒病（COVID-19）大流行正在迅速蔓延。COVID-19重症病例可迅速发展为急性呼吸窘迫综合征和多器官功能衰竭。然而，迄今为止尚无有效药物，截至2020年4月29日已导致超过30万人死亡。在此，我们报告一例使用脐带血间充质干细胞（UCB-MSCs）治疗的重症病例。
一名72岁男性因COVID-19、急性呼吸窘迫综合征、2型糖尿病、糖尿病肾病、肾功能不全和高血压入院。即使接受了包括抗病毒治疗和体外膜肺氧合在内的各种治疗方案，他的临床状况仍不断发展至危及生命。在2020年2月28日至3月8日期间，该患者接受了5次脐带血间充质干细胞静脉输注。他的血液学和生化指标，包括淋巴细胞和肾功能均有所改善。肺静态顺应性显著增加，动脉血氧分压/吸入氧分数值（PaO2/FiO2）比值保持稳定。3月10日，他接受了肺移植。
我们目前的研究结果表明，脐带血间充质干细胞治疗在治疗重症COVID-19方面可能在一定程度上显示出一些积极效果，因其可延缓疾病恶化以及对呼吸和肾功能具有一定疗效，尽管疗效有限。
